Company intelligence / Profile preview
Nanjing KAEDI Biotech, Inc.
Nanjing, Jiangsu Sheng, China
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has multiple CAR-T candidates in development, with KD-021 in Phase 1 clinical trials targeting MSLN for neoplasms. KD-025 has shown strong efficacy and good safety in animal studies with no obvious toxicities or side effects observed in early clinical infusions.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyGene therapyMonoclonal antibodyTCR-T Cell therapyUniversal CAR-T
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Porton Biologics Ltd. (Portonbio) - strategic partnership announced May 31, 2021
Beyond the preview
Go deeper on Nanjing KAEDI Biotech, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing KAEDI Biotech, Inc..